Instruct tumour cells to make antibodies against their own oncoprotein
Deliver genetic instructions so the cancer cell itself manufactures a molecule that traps its driver protein inside the cell.
Intrabodies (single-domain antibodies or designed binders expressed intracellularly) can sequester or degrade targets that small molecules cannot reach. mRNA-LNP delivery makes transient intracellular expression feasible without viral vectors, and fusion to a degron converts binding into destruction. Delivery specificity and expression level are the open questions rather than the biology.
- The undruggable drivers · The proteins that drive most cancers, such as MYC, mutant p53 and most RAS variants, still have no good drug.
Pages like this
not linked directly; found by shared links- IdeamRNA-delivered MYC decoy proteins instead of MYC inhibitors
Shares Orna Therapeutics (Eli Lilly), Moderna, Personalised neoantigen (mRNA) vaccines, The undruggable drivers.
- TechnologySelf-amplifying and circular RNA therapeutics
Shares Orna Therapeutics (Eli Lilly), Moderna, Personalised neoantigen (mRNA) vaccines.
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaDrag cancer's surface and secreted proteins to the cell's recycling bin
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaVaccines aimed only at mutations shared by every tumour cell
- IdeaFind E3 ligases that only tumours have, and build degraders around them
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- InstitutionDavid H. Koch Institute for Integrative Cancer Research at MIT
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.